

## **TEST CHANGE**

I avil a main / 1 vm		the second s	• • • • • • • • • • • • • • • • • • •	<b>•••••••••••••••••••••••••••••••••••••</b>
i elikemia/i vr	nnnoma Phenc	itvning Evailis	ation ny fiow i	winnerry
LCurrenta/ Lyr				
		71 5		, ,

3001780, LL PANEL	
Specimen Requirements:	
Patient Preparation:	
Collect:	Bone marrow. Whole blood: Green (sodium heparin), lavender (K2EDTA), or pink (K2EDTA). Tissue or fluid.
Specimen Preparation:	Bone mMarrow: Transport 1 mL heparinized bone marrow (Min: 0.5 mL*) Whole bBlood: Transport 5 mL whole blood. (Min: 1mL*) Tissue: Transport 100 mg fresh tissue suspended in tissue culture media (e.g., RPMI 1640) (Min: 100 mg*) Fluid: Transport 10-100 mL fresh fluid (Min: 3 mL*)*)- *Minimum volume is dependent on cellularity. <u>New York State Clients: Whole blood and bone marrow:</u> Transport 2 mL (Min: 1 mL) Tissue: Transport 0.2 cm3 suspended in RPMI. Fluid: Transport 0.5 mL (Min. 0.5 mL) equal parts RPMI and specimen volume. Do not send to ARUP Laboratories. Specimen must be received at performing laboratory within 48 hours of collection. For specimen requirements and direct submission instructions please contact ARUP Referral Testing at 800-242-2787 ext. 5145.
Transport Temperature:	Specimen should be received within 24 hours of collection for optimal cell viability. Bone marrow or whole blood: Room temperature. Also acceptable: Refrigerated. Tissue or fluid: Refrigerated.
Unacceptable Conditions:	Clotted or hemolyzed specimens.
Remarks:	A minimum of 10,000 viable cells is required for flow cytometry phenotyping of samples containing a very limited number of markers (may also be called antibodies or antigens). For low- count specimens, supplying clinical and diagnostic information is especially important to help ensure the most appropriate marker combinations are evaluated before the specimen is depleted of cells. Bone marrow or whole blood: Provide specimen source, CBC, Wright stained smear (if available), clinical history, differential diagnosis, and any relevant pathology reports. Tissue or Fluid: Provide specimen source, clinical history, differential diagnosis, and any relevant pathology reports. Follow up: If previous leukemia/lymphoma phenotyping was performed at another lab, the outside flow cytometry report and histograms (if possible) should accompany the specimen.



Stability:	Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Methodology:	Flow Cytometry
Performed:	Sun-Sat
Reported:	1-2 days
Note:	Flow cytometric immunophenotyping can aid in lineage assignment of acute leukemias and assist in diagnosis and classification of leukemias and lymphomas. A panel of markers is performed on each case depending on the clinical history and specimen type. Without prior history or additional information, peripheral blood specimens typically undergo a preliminary analysis for B, T, NK, and myeloid/monocytic abnormalities, while bone marrows and lymph nodes undergo additional analysis for plasma cell abnormalities. Additional markers will be run as needed to further characterize abnormal populations. Available Markers by population*: T cell: CD1a, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD25, CD26, CD30, CD200, CD279 (PD-1), TCR gamma-delta, TRBC1, Cytoplasmic CD3 B cell: CD5, CD10, CD11c, CD19, CD20, CD22, CD23, CD25, CD38, CD103, CD123, CD200, surface Kappa, surface Lambda, cytoplasmic Kappa, cytoplasmic Lambda Plasma cell: CD13, CD19, CD20, CD27, CD33, CD38, CD45, CD56, CD81, CD117, CD138, CD200, cytoplasmic Kappa, cytoplasmic Lambda Myeloid: CD11b, CD13, CD14, CD15, CD16, CD33, CD34, CD36, CD38, CD41, CD42b, CD45, CD56, CD57, CD61, CD66b, CD71, CD17, CD123, HLA-DR, myeloperoxidase, glycophorin (CD235a), TdT B lymphoblasts: CD10, CD19, CD20, CD22, CD24, CD38, CD45, CD58, CLRF2, cCD22, cCD79a Mast <u>c</u> Gell: CD2, CD25, CD30, CD117, CD123 *Not all markers will be reported in all cases. Requests for specific markers to be run must be listed on manual requisition or by footnote for electronic orders. We do not offer individual marker identification separately outside of the markers in this panel. The report will include a pathologist interpretation and a marker interpretation range corresponding to CPT codes of 2-8 markers, 9- <u>15 markers</u> <u>15markere</u> , and 16+ markers interpreted. Charges apply per marker.
CPT Codes:	88184, 88185 each additional marker; 88187 or 88188 or 88189.
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Data:	



Refer to report.

## Reference Interval:

By report